Protagonist Therapeutics, Inc (PTGX) Stock Price, Financials & Summary

Price chart

Oct 7Oct 12Oct 15Oct 20Oct 23Oct 28Nov 2Nov 5

Key dataNov 5, 2026

Open$142.03

From 52W high−14.73%

Volume582605.00

Market cap$8.75B

P/E (TTM)111.0x

P/S (TTM)31.0x

Div yield—

Key dataNov 5, 2026

Open

$142.03

From 52W high

−14.73%

Volume

582605.00

Market cap

$8.75B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

92.9x

P/E (TTM)

111.0x

RSI (14)

45.8

MomentumView details →

1D Return

−5.66%

YTD Return

+57.82%

SummaryUpdated Jun 1, 2026

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is a clinical-stage biopharmaceutical company founded in 2006 and headquartered in Newark, California. The company went public in August 2016 and specializes in discovering and developing peptide-based therapeutic drugs targeting hematology, blood disorders, and inflammatory diseases. Protagonist has evolved from a research-focused biotech startup into a company with multiple clinical-stage programs and strategic partnerships, including a significant collaboration with Janssen Biotech.

Ask drillr about Protagonist Therapeutics, Inc →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

111.0x

EV/EBITDA

92.9x

EV/Sales

28.3x

P/S (TTM)

31.0x

P/B (TTM)

10.4x

ProfitabilityView details →

Gross Margin

99.86%

Net Margin

29.40%

EBITDA Margin

30.45%

ROE (TTM)

9.85%

ROA (TTM)

9.36%

Asset Turnover

0.36x

GrowthView details →

Revenue YoY

+34.81%

EPS YoY

+46.76%

FCF YoY

+256.27%

Revenue CAGR 3Y

+20.07%

EPS CAGR 3Y

—

EBITDA YoY

+110.49%

MomentumView details →

1D Return

−5.66%

YTD Return

+57.82%

1Y Return

+72.78%

RSI (14)

45.8

vs 50D SMA

−2.88%

vs 200D SMA

+17.06%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

21.71x

Quick Ratio

21.71x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$2.29

EPS Surprise

0.88%

Beats (12Q)

8/12

Next Q EPS Est

−$0.32

Avg Surprise (4Q)

825.87%

Rev Surprise

0.68%

Financials snapshotView financials →

Revenue (TTM)

281.99M

Net Income (TTM)

82.91M

Op. CF (TTM)

131.20M

Next earningsMar 2, 2027 →

Latest newsMore news →

Protagonist Therapeutics announced a $300 million share repurchase program.10h ago

Protagonist Therapeutics reported third-quarter 2026 revenue of $274.4 million and net income of $220.0 million, with cash and marketable securities of $834.6 million.10h ago

Similar companies

ST诺泰688076.SH GenFleet Therapeutics (Shanghai) Inc.02595.HK TG Therapeutics, Inc.TGTX Krystal Biotech, Inc.KRYS Crinetics Pharmaceuticals, Inc.CRNX ImmunityBio, Inc.IBRX Find similar companies →

Latest newsMore news →

Protagonist Therapeutics announced a $300 million share repurchase program.10h ago Protagonist Therapeutics reported third-quarter 2026 revenue of $274.4 million and net income of $220.0 million, with cash and marketable securities of $834.6 million.10h ago